# Jounce Therapeutics

Source: https://onco.cc/companies/jounce-therapeutics/  
OnCo record `jounce-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Jounce Therapeutics developed treatments that help the immune system attack cancer, along with tests to predict who would benefit. Concentra Biosciences bought it in 2023.

## Summary

Jounce Therapeutics was a clinical-stage immunotherapy company focused on discovering and developing cancer immunotherapies and predictive biomarkers, listed on Nasdaq as JNCE. On 3 May 2023 Concentra Biosciences, LLC completed a tender offer for all Jounce shares at $1.85 a share in cash plus a non-tradeable contingent value right, then merged its subsidiary into Jounce, making Jounce a wholly owned Concentra subsidiary. Jounce's shares stopped trading on Nasdaq.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Jounce Therapeutics, Inc.
- HQ: Cambridge, MA
- Type: biotech

## Notes

- Concentra Biosciences is not a company record in OnCo, so acquiredBy is not set.
- Named product candidates are not stated in the sources read; none recorded.
- Founding year not stated (2013 is Third Rock's year of investment).

## Sources

- Closing of tender offer (SEC exhibit, 3 May 2023): https://www.sec.gov/Archives/edgar/data/1640455/000164045523000084/jnce-exhibit991.htm
- Third Rock Ventures portfolio entry: https://www.thirdrockventures.com/portfolio/jounce

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- companies: [Third Rock Ventures](https://onco.cc/companies/third-rock-ventures/)

---
JSON: https://onco.cc/api/v1/entities/jounce-therapeutics.json